Rights issue in Oncopeptides AB (SE) — SEK 314 million

Carnegie acted as joint bookrunner in the SEK 314 million rights issue in Oncopeptides.

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.